Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) was $21.26 for the day, down -9.92% from the previous closing price of $23.6. In other words, the price has decreased by -$9.92 from its previous closing price. On the day, 8.44 million shares were traded. ACAD stock price reached its highest trading level at $21.86 during the session, while it also had its lowest trading level at $20.02.
Ratios:
Our analysis of ACAD’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.17. For the most recent quarter (mrq), Quick Ratio is recorded 2.83 and its Current Ratio is at 2.91. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $22.
Guggenheim Downgraded its Buy to Neutral on January 03, 2025, whereas the target price for the stock was revised from $23 to $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 15 ’25 when Schneyer Mark C. sold 3,498 shares for $23.65 per share. The transaction valued at 82,728 led to the insider holds 43,447 shares of the business.
GAROFALO ELIZABETH A. sold 1,600 shares of ACAD for $41,560 on Sep 02 ’25. The Director now owns 25,382 shares after completing the transaction at $25.98 per share. On Aug 18 ’25, another insider, Schneyer Mark C., who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 22,000 shares for $25.18 each. As a result, the insider received 554,024 and left with 40,130 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3586821888 and an Enterprise Value of 2881119744. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.98, and their Forward P/E ratio for the next fiscal year is 25.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 69.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.52 while its Price-to-Book (P/B) ratio in mrq is 4.36. Its current Enterprise Value per Revenue stands at 2.828 whereas that against EBITDA is 27.712.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.77, which has changed by 0.37338507 over the last 52 weeks, in comparison to a change of 0.15535986 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $26.65, while it has fallen to a 52-week low of $13.40. The 50-Day Moving Average of the stock is -12.49%, while the 200-Day Moving Average is calculated to be 6.73%.
Shares Statistics:
ACAD traded an average of 1.89M shares per day over the past three months and 2617450 shares per day over the past ten days. A total of 168.61M shares are outstanding, with a floating share count of 167.39M. Insiders hold about 0.79% of the company’s shares, while institutions hold 101.15% stake in the company. Shares short for ACAD as of 1756425600 were 9278091 with a Short Ratio of 4.90, compared to 1753920000 on 11030686. Therefore, it implies a Short% of Shares Outstanding of 9278091 and a Short% of Float of 8.62.
Earnings Estimates
The company has 14.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.13, with high estimates of $0.27 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.89 and $0.42 for the fiscal current year, implying an average EPS of $0.56. EPS for the following year is $0.87, with 14.0 analysts recommending between $1.93 and $0.17.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 17 analysts. It ranges from a high estimate of $291.06M to a low estimate of $271.8M. As of. The current estimate, Acadia Pharmaceuticals Inc’s year-ago sales were $250.4MFor the next quarter, 17 analysts are estimating revenue of $286.69M. There is a high estimate of $306.5M for the next quarter, whereas the lowest estimate is $278.8M.
A total of 19 analysts have provided revenue estimates for ACAD’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.06B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $957.8MBased on 18 analysts’ estimates, the company’s revenue will be $1.19B in the next fiscal year. The high estimate is $1.33B and the low estimate is $1.13B.
